ClinicalTrials.gg
RecruitingNCT07094971Updated Aug 3, 2025

Pure Impact Treatment to Strengthen and Tone Abdomen, Quadriceps and Glutes Muscles

An interventional study of Pure Impact in Muscle Tone and Muscle Strength, sponsored by Sofwave Medical LTD. Recruiting at 1 site in United States. Open to participants aged 25 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Sofwave Medical LTD · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
25 Years to 60 Years
Sex
All
01

Study summary

Open-label, non-randomized, prospective, single-center, self-controlled clinical study.

Read the detailed description

Eligible subjects will be divided into two groups. The test group will include 15-22 subjects who will be treated to revive their body's functional potential, and the control group will include 15-22 subjects, who will not be treated.

The Test group will arrive to 6 Pure Impact sessions and to 4 weeks follow-up visit; while the control group will arrive to 3 visits, which are equivalent to before first treatment, last treatment (5 weeks after first visit) and 4 weeks after the second visit (equivalent to 4 weeks follow-up visit of the test group).

Subjects of the test group will receive 6 Pure Impact treatments on the abdomen and quadriceps, and/or hamstring and glutes once a week.

First treatment may be administered after the enrolment and screening at the first visit, or it may occur later following the enrolment and screening activities based on site scheduling availabilities.

Overall, all treatments are done within 6 weeks.

All subjects will return to the clinic for follow-up visit at 4±1 weeks post last treatment.

02

Conditions studied

  • Muscle Tone
  • Muscle Strength

Keywords

  • Abdomen
  • Hamstring
  • Quadriceps
  • Glutes
  • skin laxity
  • muscle tone
  • muscle strength
  • muscle firm
03

In context

Lead sponsor

Sofwave Medical LTD is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects ≥ 25 years of age and ≤ 60 years of age.
  2. Not pregnant or lactating and must be either , surgically sterilized, or using a medically acceptable form of at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
  3. Desire to undergo treatments on abdomen and quadriceps and/or on hamstring and glutes for strength and tone muscles.
  4. Subject agrees to maintain their weight within 5% of total body weight and avoid significant dietary or exercise changes during the study.
  5. Able and willing to comply with all visits, treatments and evaluations schedules and requirements.
  6. Willing to have research photos taken of treatment areas.
  7. Able to understand and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
  2. Medical disorder that would hinder the wound healing or immune response (such as blood disorder) including but not limited to arterial circulation disorders in lower limbs, inflammatory disease, etc.
  3. Active or history of malignancy in the past 5 years.
  4. Suffering from significant concurrent illness, such as cardiac disorders, sensory disturbances, diabetes (type I or II), epilepsy, lupus, porphyria, pertinent neurological disorders, uncontrolled hypertension, or liver or kidney disease (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process).
  5. History of /immune deficiency disorders (including infection or AIDS) or currently using immunosuppressive medications.
  6. \< 18 or >35kg/m2
  7. Non-stable weight nominally ±5% in the past month.
  8. Active implanted device such as a pacemaker, defibrillator, drug delivery system or any other metallic or electric implant anywhere in the body.
  9. Permanent implant in the treated area such as metal plates, screws and metal piercing, silicone implants or an injected chemical substance, unless deep enough in the periosteal plane.
  10. History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.) at the last 2 years.
  11. History of prior surgery in the treated areas at the last 2 years.
  12. Excessive subcutaneous fat on the treated areas.
  13. Abdominal or inguinal hernia
  14. Any active condition in the treatment area, such as open wounds, sores, psoriasis, eczema, and rash.
  15. Any sensitivity for hydrogel (Pure Impact electrodes pads are made of hydrogel).
  16. History of chronic drug or alcohol abuse.
  17. Muscle atrophy.
  18. Need for muscle rehabilitation.
  19. Persistent pain at the treated area.
  20. Inability to understand the protocol or to give .
  21. Unable or unwilling to comply with the study requirements and procedures.
  22. Currently enrolled in a clinical study of any other unapproved drug or device.
  23. Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
  24. Presence of any active systemic or local infections.
  25. Significant scarring in the area to receive study treatment.
  26. Suspected or diagnosed heart problems.
  27. Areas of the skin that lack normal sensation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Muscle strength

    Pure Impact is an EMS module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated.

    Device: Pure Impact

  • No intervention
    Control

    Control group will be followed but will not be treated.

Interventions

  • DevicePure Impact

    Pure Impact is an EMS module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated.

06

What researchers measure

Primary outcomes

  1. Improvement rate of the muscles strength

    Higher improvement rate of the muscles strength tests at the test group compared to the control group using series of exercises tests including questionnaire, and a functional evaluation of the muscles of the abdomen, quadriceps, and glutes.

    Time frame: 1 Month post last treatment follow up visit

07

Study locations

1 of 1 sites recruiting
  • Movassaghi Plastic Surgery & Ziba Medical Spa
    Eugene, Oregon 97401, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07094971
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Jul 11, 2025
Primary completion
Jul 10, 2026 (estimated)
Completion
Jul 10, 2026 (estimated)
Last update
Aug 3, 2025

Study contacts

Shlomit Mann, MSc
Contact
shlomit@sofwave.com
047800268
Ruthie Amir, MD
Contact
ruthie@sofwave.com
043003164
Ahlam Safadi, BSC
study director · Sofwave Medical LTD

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion